Equities

BridgeBio Pharma Inc

BridgeBio Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.96
  • Today's Change-0.77 / -2.88%
  • Shares traded1.66m
  • 1 Year change-9.04%
  • Beta1.0863
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy3
Outperform11
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for BridgeBio Pharma Inc have a median target of 46.00, with a high estimate of 70.00 and a low estimate of 37.00. The median estimate represents a 77.20% increase from the last price of 25.96.
High169.6%70.00
Med77.2%46.00
Low42.5%37.00

Earnings history & estimates in USD

On Aug 01, 2024, BridgeBio Pharma Inc reported 2nd quarter 2024 losses of -0.39 per share. This result exceeded the -1.06 consensus loss of the 12 analysts covering the company and exceeded last year's 2nd quarter results by 60.20%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate-3.73%
BridgeBio Pharma Inc reported annual 2023 losses of -3.95 per share on Feb 22, 2024.
Average growth rate-15.15%
More ▼

Revenue history & estimates in USD

BridgeBio Pharma, Inc. had 2nd quarter 2024 revenues of 2.17m. This missed the 3.57m consensus estimate of the 7 analysts following the company. This was 18.73% above the prior year's 2nd quarter results.
Average growth rate+2,997.89%
BridgeBio Pharma, Inc. had revenues for the full year 2023 of 9.30m. This was 88.02% below the prior year's results.
Average growth rate+147.21%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.